Stocktwits on MSN

MIRM stock clocks best day in 4.5 months on liver disease trial data: Retail eyes buyout at a premium

In Mirum’s trial, volixibat delivered statistically significant and clinically meaningful reductions in cholestatic pruritus or an intense, often debilitating itching caused by liver diseases. ・The ...
Nasdaq

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent ...

New York, New York--(Newsfile Corp. - August 7, 2025) - OS Therapies (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) ...

Viridian shares climb as trial data reinforces position in thyroid eye disease market

Viridian Therapeutics, Inc. VRDN shares are up on Tuesday as the company announced positive topline results from its REVEAL-2 ...
The Manila Times

ISOThrive Reports Highly Statistically Significant Phase 2 Data for MHS-1031 in NERD Patients at DDW 2026

The Phase 2 study is being conducted under an IND with the FDA and includes leading investigators from Vanderbilt University, ...
Endovascular Today

Data Presented From Pilot Trial of InVera Infusion Device for Chronic Venous Disease

InVera Medical announced 12-month results from its pilot clinical study of the InVera infusion device for the treatment of ...
The Manila Times

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Analysis demonstrates statistically significant reduction in the severity of surgical wound infections, with potential to ...